Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study

American Heart Journal

Volumn 159, Issue 5, 2010, Pages 795-802

  Bertrand, Michel E ^a   Ferrari, Roberto ^b   Remme, Wilhelm J ^c   Simoons, Maarten L ^d   Deckers, Jaab W ^d   Fox, K M ^e  

^a Lille Heart Institute   (France)

^b UNIVERSITY OF FERRARA   (Italy)

^c Sticares Cardiovascular Research Foundation   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; NITRATE; PERINDOPRIL; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; FEMALE; FOLLOW UP; HEART ARREST; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; SECONDARY PREVENTION;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CORONARY ARTERY DISEASE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERINDOPRIL; PROPORTIONAL HAZARDS MODELS;

EID: 77951656589     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.12.042     Document Type: Article

References (22)

1. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28 (2007) 2375-2414
2. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
3. National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care: partial update (2006), Royal College of Physicians, London, UK
4. McInnes G.T. Antihypertensive drugs in combination: additive or greater than additive?. J Hum Hypertens 21 (2007) 914-916
5. Gojanovic B., Feihl F., Liaudet L., et al. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J Renin Angiotensin Aldosterone Syst 9 (2008) 1-9
6. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
7. Gomma A.H., and Fox K.M. The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 15 (2001) 169-179
8. Fletcher G.F., Bufalino V., Costa F., et al. Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. Am J Cardiol 99 (2007) 1E-35E
9. Ferrari R. Optimizing the treatment of hypertension and stable coronary artery disease : clinical evidence for fixed-combination perindopril/amlodipine. Curr Med Res Opin 24 (2008) 3543-3557
10. Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 (2006) 1213-1225
11. Ceconi C., Fox K.M., Remme W.J., et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 73 (2007) 237-246
12. Rodriguez-Granillo G.A., De Winter S., Bruining N., et al. Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study. Eur Heart J 28 (2007) 2326-2331
13. Bruining N., De Winter S., Roelandt J.R.T.C., et al. Coronary calcium significantly affects the results of quantitative coronary ultrasound in atherosclerosis progression-regression studies. Eur Heart J 29 Suppl (2008) 786 [Abstract]
14. Nissen S.E., Tuzcu E.M., Libby P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292 (2004) 2217-2225
15. Poole Wilson P.A., Lubsen J., Kirwan B.A., et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 364 (2004) 849-857
16. Braunwald E., Domanski M.J., Fowler S.E., et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
17. Pitt B., O'Neill B., Feldman R., et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 87 (2001) 1058-1063
18. Remme W.J. Secondary prevention of coronary artery disease and the choice of the ACE inhibitor why EUROPA and not PEACE. Cardiovasc Drugs Ther 21 (2007) 405-407
19. Ceconi C., Francolini G., Olivares A., et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 577 (2007) 1-6 [Abstract]
20. Zanchetti A., Bond M.G., Hennig M., et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106 (2002) 2422-2427
21. Meurin P. The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension. Am J Cardiovasc Drugs 6 (2006) 327-334
22. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290 (2003) 2805-2816